N

NRX Pharmaceuticals
D

NRXP

1.23000
USD
-0.02
(-1.20%)
مفتوح الان
حجم التداول
414
الربح لكل سهم
0
العائد الربحي
0
P/E
-0
حجم السوق
13,221,907
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMZN
    -3.000
    (-1.60%)
    213.01 USD
    COST
    -5.53
    (-0.67%)
    926.09 USD
    CVS
    -0.300
    (-0.50%)
    60.020 USD
    K
    KR
    0.580
    (1.06%)
    55.080 USD
    R
    RAD
    -0.13430
    (-17.23%)
    0.64500 USD
    S
    SFM
    0.880
    (0.88%)
    100.780 USD
    TGT
    -3.350
    (-2.23%)
    147.010 USD
    W
    WBA
    -0.055
    (-0.46%)
    11.805 USD
    WMT
    1.140
    (1.66%)
    85.1 USD
    المزيد
الأخبار
المقالات

العنوان: NRX Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.